Outcomes associated with early rheumatoid arthritis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 5, 2006, Pages 495-508

  Scott, David L ^a   Lempp, Heidi K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Disability; Disease outcome; Economics; Radiological damage; Rheumatoid arthritis

Indexed keywords

ANALGESIC AGENT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ARTHRALGIA; BONE EROSION; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DRUG COST; EVIDENCE BASED MEDICINE; FATIGUE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; JOINT INJURY; LONG TERM CARE; LOW DRUG DOSE; MEDICAL DECISION MAKING; MORTALITY; OUTCOME ASSESSMENT; PATIENT SELECTION; PHYSICAL DISABILITY; PHYSIOTHERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SELF CONCEPT; SYNOVITIS; TREATMENT PLANNING; UNEMPLOYMENT; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VOCATIONAL REHABILITATION; WORK DISABILITY;

EID: 33750989647     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.5.495     Document Type: Review

References (90)

1. St Clair EW, van der Heijde DM, Smolen JS et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50, 3432-3443 (2004).
2. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 52, 3381-3390 (2005).
3. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26-37 (2006).
4. Mottonen T, Hannonen P. Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353, 1568-1573 (1999).
5. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263-269 (2004).
6. Emery P. Treatment of rheumatoid arthritis. Br. Med. J. 332, 152-155 (2006).
7. Dixon WG, Symmons DP. Does early rheumatoid arthritis exist? Best Pract. Res. Clin. Rheumatol. 19, 37-53 (2005).
8. Albers JM, Paimela L, Kurki P et al. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann. Rheum. Dis. 60, 453-458 (2001).
9. Welsing PM, van Gestel AM, Swinkels HL et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 44, 2009-2017 (2001).
10. Machold KP, Nell VP, Stamm TA et al. The Austrian early arthritis registry. Clin. Exp. Rheumatol. 21(Suppl.31), S113-S117 (2003).
11. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 24, 1308-1315 (1981).
12. Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J. Rheumatol. 22, 639-643 (1995).
13. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J. Rheumatol. 23, 1407-1417 (1996).
14. Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford) 45, 885-889 (2006).
15. Suurmeijer TP, Waltz M, Moum T et al. Quality of life profiles in the first years of rheumatoid arthritis: results from the EURIDISS longitudinal study. Arthritis Rheum. 45, 111-121 (2001).
16. Gerber LH, Furst G, Yarboro C, el-Gabalawy H. Number of active joints, not diagnosis, is the primary determinant of function and performance in early synovitis. Clin. Exp. Rheumatol. 21(5 Suppl. 31), S65-S70 (2003).
17. Treharne GJ, Kitas GD, Lyons AC, Booth DA. Well-being in rheumatoid arthritis: the effects of disease duration and psychosocial factors. J. Health Psychol. 10, 457-474 (2005).
18. Mottonen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M. Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum. 39, 996-1005 (1996).
19. Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br. J. Rheumatol. 35, 1101-1105 (1996).
20. Sokka T, Hannonen P. Utility of disease modifying antirheumatic drugs in "sawtooth" strategy. A prospective study of early rheumatoid arthritis patients up to 15 years. Ann. Rheum. Dis. 58, 618-622 (1999).
21. Harrison B, Symmons D. Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. II. Outcome at three years. Rheumatology (Oxford) 39, 939-949 (2000).
22. Young A, Dixey J, Cox N et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 39, 603-611 (2000).
23. Lindqvist E, Saxne T, Geborek P, Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann. Rheum. Dis. 61, 1055-1059 (2002).
24. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 46, 357-365 (2002).
25. Schumacher HR Jr, Habre W, Meador R, Hsia EC. Predictive factors in early arthritis: long-term followup. Semin. Arthritis Rheum. 33, 264-272 (2004).
26. Tengstrand B, Ahlmen M, Hafstrom I. The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. J. Rheumatol. 31, 214-222 (2004).
27. Verstappen SM, van Albada-Kuipers GA, Bijlsma JW et al. Utrecht Rheumatoid Arthritis Cohort Study Group (SRU). A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann. Rheum. Dis. 64, 38-43 (2005).
28. Makinen H, Kautiainen H, Hannonen P, Sokka T. Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. a 5-year followup study. J. Rheumatol. 32, 796-800 (2005).
29. Stockman A, Tait BD, Wolfe R et al. Clinical, laboratory and genetic markers associated with erosions and remission in patients with early inflammatory arthritis: a prospective cohort study. Rheumatol. Int. 26(6) 500-509 (2005).
30. Bruynesteyn K, van der Heijde D, Boers M et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Hejde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum. 46, 913-920 (2002).
31. Brook A, Corbett M. Radiographic changes in early rheumatoid disease. Ann. Rheum. Dis. 36, 71-73 (1977).
32. Fex E, Jonsson K, Johnson U, Eberhardt K. Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. Br. J. Rheumatol. 35, 1106-1115 (1996).
33. Drossaers-Bakker KW, Amesz E, Zwinderman AH, Breedveld FC, Hazes JM. A comparison of three radiologic scoring systems for the long-term assessment of rheumatoid arthritis: findings of an ongoing prospective inception cohort study of 132 women followed up for a median of twelve years. Arthritis Rheum. 43, 1465-1472 (2000).
34. Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D et al. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 60, 924-927 (2001).
35. Machold KP, Stamm TA, Eberl GJ et al. Very recent onset arthritis - clinical, laboratory, and radiological findings during the first year of disease. J. Rheumatol. 29, 2278-2287 (2002).
36. Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary care-based inception cohort of patients. Rheumatology (Oxford) 41, 246-252 (2002).
37. Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann. Rheum. Dis. 62, 611-616 (2003).
38. Paulus HE, Oh M, Sharp JT et al. Western Consortium of Praticing Rheumatologists. Correlation of single time-point damage scores with observed progression of radiographic damage during the first 6 years of rheumatoid arthritis. J. Rheumatol. 30, 705-713 (2003).
39. Sanmarti R, Gomez A, Ercilla G et al. Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting. Rheumatology (Oxford) 42, 1044-1049 (2003).
40. Guillemin F, Gerard N, van Leeuwen M, Smedstad LM, Kvien TK, van den Heuvel W: EURIDISS Group. Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients. J. Rheumatol. 30, 2585-2589 (2003).
41. Dixey J, Solymossy C, Young A. Early RA study. Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS). J. Rheumatol. 69, 48-54 (2004).
42. Plant MJ, Jones PW, Saklatvala J, Ollier WE, Dawes PT. Patterns of radiological progression in early rheumatoid arthritis - results of an 8 year prospective study. J. Rheumatol. 25, 417-426 (1998).
43. Egsmose C, Lund B, Borg G et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow up of a prospective double blind placebo controlled study. J. Rheumatol. 22, 2208-2213 (1995).
44. Mottonen T, Paimela. L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M. Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum. 39, 996-1005 (1996).
45. Kaarela K, Kautiainen H. Continuous progression of radiological destruction in seropositive RA. J. Rheumatol. 24, 1280-1284 (1997).
46. Wick MC, Lindblad S, Weiss RJ, Klareskog L, van Vollenhoven RF. Clinical and radiological disease-course in a Swedish DMARD-treated early RA-inception cohort: an observational study. Scand. J. Rheumatol. 33, 380-384 (2004).
47. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis. Arthritis Rheum. 41, 1571-1582 (1998).
48. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 42, 1854-1860 (1999).
49. Welsing PM, Van Gestel AM, Swinkels HL, Kiemeney LA, Van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 44, 2009-2017 (2001).
50. Odegard S, Landewe R, van der Heijde D, Kvien TK, Mowinckel P, Uhlig T. Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. Arthritis Rheum. 54, 68-75 (2006).
51. Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin. Exp. Rheumatol. 23(5 Suppl. 39), S43-S52 (2005).
52. Scott DL, Pugner K, Kaarela K et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 39, 122-132 (2000).
53. Wiles N, Dunn G, Barrett E, Silman A, Symmons D. Associations between demographic and disease-related variables and disability over the first five years of inflammatory polyarthritis: a longitudinal analysis using generalized estimating equations. J. Clin Epidemiol. 53, 988-996 (2000).
54. Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 46, 2310-2319 (2002).
55. Welsing PM, Fransen J, van Riel PL. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum. 52, 2616-2624 (2005).
56. Salaffi F, Stancati A, Neri R, Grassi W, Bombardieri S. Measuring functional disability in early rheumatoid arthritis: the validity, reliability and responsiveness of the Recent-Onset Arthritis Disability (ROAD) index. Clin. Exp. Rheumatol. 23(5 Suppl. 39), S31-S42 (2005).
57. West E, Jonsson SW. Health-related quality of life in rheumatoid arthritis in Northern Sweden: a comparison between patients with early RA, patients with medium-term disease and controls, using SF-36. Clin. Rheumatol. 24, 117-122 (2005).
58. Soderlin MK, Kautiainen H, Skogh T, Leirisalo-Repo M. Quality of life and economic burden of illness in very early arthritis. A population based study in southern Sweden. J. Rheumatol. 31, 1717-1722 (2004).
59. Sharpe L, Sensky T, Brewin CR, Allard S. Characteristics of handicap for patients with recent onset rheumatoid arthritis: the validity of the Disease Repercussion Profile. Rheumatology (Oxford) 40, 1169-1174 (2001).
60. Young A, Dixey J, Kulinskaya E et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann. Rheum. Dis. 61, 335-340 (2002).
61. Treharne GJ, Lyons AC, Booth DA, Mason SR, Kitas GD. Reactions to disability in patients with early versus established rheumatoid arthritis. Scand. J. Rheumatol. 33, 30-38 (2004).
62. Treharne GJ, Kitas GD, Lyons AC, Booth DA. Well-being in rheumatoid arthritis: the effects of disease duration and psychosocial factors. J. Health Psychol. 10, 457-474 (2005).
63. Witney AG, Treharne GJ, Tavakoli M et al. The relationship of medical, demographic and psychosocial factors to direct and indirect health utility instruments in rheumatoid arthritis. Rheumatology (Oxford) 45, 975-981 (2006).
64. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 46, 2010-2019 (2002).
65. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann. Rheum. Dis. 64, 1595-1601 (2005).
66. Kroot EJA, van Leeuwen MA, van Rijswijk MH et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann. Rheum. Dis. 59, 954-958 (2000).
67. Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann. Rheum. Dis. 58, 11-14 (1999).
68. Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 110, 1774-1779 (2004).
69. Pugner KM, Scott DL, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin. Arthritis Rheum. 29, 305-320 (2000).
70. Hallert E, Husberg M, Skogh T. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology (Oxford) 45, 325-331 (2006).
71. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 44, 1169-1175 (2005).
72. Westhovens R, Boonen A, Verbruggen L et al. Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin. Rheumatol. 24, 615-619 (2005).
73. Puolakka K, Kautiainen H, Mottonen T et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum. 50, 55-62 (2004).
74. Nordmark B, Blomqvist P, Andersson B et al. A two-year follow-up of work capacity in early rheumatoid arthritis: a study of multidisciplinary team care with emphasis on vocational support. Scand. J. Rheumatol. 35, 7-14 (2006).
75. Gilworth G, Chamberlain MA, Harvey A et al. Development of a work instability scale for rheumatoid arthritis. Arthritis Rheum. 49, 349-354 (2003).
76. Yelin E. Is early intervention worth it? J. Rheumatol. Suppl. 72, 36-38 (2005).
77. Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P. Framework for design and evaluation of complex interventions to improve health. Br. Med. J. 321, 694-696 (2000).
78. Thornicroft G, Rose D. Health service research: is there anything to learn from mental health? J. Health Ser. Res. Policy 10, 1-2 (2005).
79. Thornicroft G, Tansella M. Growing recognition of the importance of service user involvement in mental health service planning and evaluation. Epidemiol. Psichiatr. Soc. 14, 1-3 (2005).
80. Camberlin J. User/consumer involvement in mental health service delivery. Epidpeiol. Psichatr. Soc. 14, 10-14 (2005).
81. Lapsley P, Groves T. The patients journey: travelling through life with chronic illness. Br. Med. J. 329, 598-584 (2004).
82. Green J, Britten N. Qualitative research and evidence based medicine. Br. Med. J. 316, 1230-1232 (1998).
83. Lempp H, Scott D, Kingsley GH. The personal impact of rheumatoid arthritis on patients' identity: a qualitative study. Chronic Illness 2, 109-120 (2006).
84. Lempp H, Scott D, Kingsley G. Patients' views on the quality of health care for rheumatoid arthritis. Rheumatology (2006) (Epub ahead of print).
85. Simpson C, Franks C, Morrison C, Lempp H. The patient's journey: rheumatoid arthritis. Br. Med. J. 331, 887-889 (2005).
86. Bykerk VP, Keystone EC. What are the goals and principles of management in the early treatment of rheumatoid arthritis? Best Pract. Res. Clin. Rheumatol. 19, 147-161 (2005).
87. Kingsley GH, Khoshaba B, Smith CM, Choy EH, Scott DL. Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria. Rheumatology (Oxford) 44, 629-632 (2005).
88. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor-α agents in rheumatoid arthritis. Arthritis Rheum. 48, 313-318 (2003).
89. Wiles NJ, Lunt M, Barrett EM et al. Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum. 44, 1033-1042 (2001).
90. Vers tappen SM, Jacobs JW, Bijlsma JW et al. Utrecht Arthritis Cohort Study Group. Five-year follow up of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum. 48, 1797-1807 (2003).